WO2018134464A1 - Moduladores de los receptores a3 de adenosina - Google Patents
Moduladores de los receptores a3 de adenosina Download PDFInfo
- Publication number
- WO2018134464A1 WO2018134464A1 PCT/ES2018/070039 ES2018070039W WO2018134464A1 WO 2018134464 A1 WO2018134464 A1 WO 2018134464A1 ES 2018070039 W ES2018070039 W ES 2018070039W WO 2018134464 A1 WO2018134464 A1 WO 2018134464A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyridin
- cyano
- thiazol
- piperidine
- carboxylic acid
- Prior art date
Links
- 0 *c1c(C#N)[s]c(NC(c2ccc(N(CC3)CCC3C(O)=O)nc2)=O)n1 Chemical compound *c1c(C#N)[s]c(NC(c2ccc(N(CC3)CCC3C(O)=O)nc2)=O)n1 0.000 description 1
- KXAXANGVOLTRLC-UHFFFAOYSA-N NCC(c(cccc1)c1F)=O Chemical compound NCC(c(cccc1)c1F)=O KXAXANGVOLTRLC-UHFFFAOYSA-N 0.000 description 1
- WBGWZMJBTPTDDN-UHFFFAOYSA-N Nc1c(-c(cccc2)c2F)nc(N)[s]1 Chemical compound Nc1c(-c(cccc2)c2F)nc(N)[s]1 WBGWZMJBTPTDDN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to derivatives of 1- (5- (thiazol-2-ylcarbamoyl) pyridin-2-yl) piperidine-4-carboxylic acid as modulators of adenosine A 3 receptors.
- Other aspects of the present invention are a process for preparing said compounds; pharmaceutical compositions comprising an effective amount of said compounds; the use of the compounds in the manufacture of a medicament to treat pathological conditions or diseases that can be improved by modulation of the A 3 adenosine receptors.
- adenosine are mediated through at least four specific membrane receptors that are classified as Ai, A 2 A, A 2 B and A 3 receptors and belong to the family of G-protein coupled receptors.
- Ai receptors and A 3 decrease intracellular levels of cyclic adenosine monophosphate (cAMP) by coupling to inhibitory G proteins (G ⁇ ) that inhibit the enzyme adenylate cyclase.
- G ⁇ inhibitory G proteins
- the A 2 A and A 2 B receptors are coupled to stimulant G proteins (G s ) that activate the enzyme adenylate cyclase and increase intracellular cAMP levels.
- G s stimulant G proteins
- Adenosine A 3 receptor modulators are being studied as emerging treatments for bowel inflammation.
- a 3 adenosine (A 3 AR) receptors are overexpressed in different autoimmune pathologies such as Crohn's disease, rheumatoid arthritis and psoriasis, so that this receptor has been considered an important target for combat said autoimmune inflammatory diseases.
- a 3 AR adenosine receptors
- the anti-inflammatory target A (3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease.
- the well-known agonist of A 3 AR was used in mice to improve intestinal inflammation and spontaneous colitis. Stimulation of the A 3 ARs was able to markedly reduce the colonic levels of proinflammatory cytosines such as IL-1, IL-6 and IL-12 (Mabley, J .; et al, The adenosine A 3 agonist receptor, N6- (3 -iodobenzyl) - adenosine-5'-N-methyluronamide, is protective in two murine models of colitis. Eur. J. Pharmacol. 2003, 466, 323-329).
- a 3 adenosine receptors are widely distributed in the central nervous system, but at low levels and with reduced affinity.
- the role of A 3 ARs in various pathophysiological conditions of the brain is controversial, although there are sufficient indications that point to an important role of these receptors in neurotransmission (Boison, D. Adenosine as a modulator of brain activity. Drug News Perspect. 2007 , 20, 607-611; Burnstock, G .; et al, Adenosine and ATP receptors in the brain. Curr. Top. Med. Chem. 201 1, 11, 973-1011).
- a 3 ARs play a protective role in the first phase of ischemia by reducing transmission synaptic (Pugliese, AM; et al, Brief, repeated, oxygen-glucose deprivation episodes protect neurotransmission from a longer ischemic episode in the in vitro hippocampus: role of adenosine receptors. Br. J. Pharmacol. 2003, 140, 305-314) .
- adenosine through the A 3 receptor, can mediate vascular protection and help decrease the size of myocardial infarction by a mechanism that involves PKC, activation of KATP channels, phosphorylation of p38MAPKs and glycogen synthase kinase ( Maddock, HL; et al, Adenosine A 3 receptor activation protects the myocardium from reperfusion / reoxygenation injury. Am. J. Physiol .: Heart Circ. Physiol. 2002, 283, H1307-H1313).
- Arteriosclerosis a multifactorial disease of the large arteries, is the leading cause of heart disease and stroke worldwide.
- Epidemiological studies have discovered several environmental and genetic risk factors associated with this disease. More recently, it has been shown that adenosine through the activation of A 3 ARs stimulates vascular endothelial growth factor secretion (VEGF) and cell foam formation, and this effect is strongly reduced by treatment with adenosine A 3 receptor antagonists.
- VEGF vascular endothelial growth factor secretion
- a 3 AR antagonists may be of interest to block important steps in the development of atherosclerotic plaque (Gessi, S .; Foet al, Adenosine modulates HIF-1 ⁇ alpha ⁇ , VEGF, IL -8, and foam cell formation in a human model of hypoxic foam cells.
- Arterioscler, Thromb., Vasc. Biol. 2010, 30, 90-97 the potential use of A 3 AR antagonists may be of interest to block important steps in the development of atherosclerotic plaque (Gessi, S .; Foet al, Adenosine modulates HIF-1 ⁇ alpha ⁇ , VEGF, IL -8, and foam cell formation in a human model of hypoxic foam cells.
- Arterioscler, Thromb., Vasc. Biol. 2010, 30, 90-97 Arterioscler, Thromb., Vasc. Biol. 2010, 30, 90-97.
- ADENOSINE 3 RECEPTORS IN THE IMMUNE SYSTEM A 3 ARs are present in immune cells and participate in the immune response of inflammatory processes. Numerous results from in vitro and in vivo studies suggest that the activation of A 3 ARs can be both pro-inflammatory and anti-inflammatory depending on the type of cell examined or the animal species considered. (Baraldi PG et al, Medicinal Chemistry of A3 Adenosine Receptor Modulators: Pharmacological Activities and Therapeutic Implications, J. Med. Chem. 2012, 55, 5676-5703, and their references).
- a 3 ARs are present in human eosinophils, coupled to cell activation signaling pathways, and are capable of protecting eosinophils from apoptosis and inhibiting the chemotaxis process.
- An overexpression of A 3 AR has also been detected in lymphocytes and in Jurkat cells, a human leukemic cell line, being associated with the inhibition of the activity of the enzyme adenylate cyclase and calcium modulation. In macrophages, the activation of A 3 AR seems to indicate an anti-inflammatory effect thereof.
- adenosine in the regulation of the respiratory system is based on the high levels of adenosine found in bronchoalveolar lavage (BAL), blood and condensed exhaled air of patients with asthma and chronic obstructive pulmonary disease (COPD).
- BAL bronchoalveolar lavage
- COPD chronic obstructive pulmonary disease
- a 3 ARs have been involved in inflammatory processes, playing an important role in both pro and anti-inflammatory responses, depending on their function in different cell types (Salvatore, CA; et al, Disruption of the A 3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol.Chem. 2000, 275, 4429-4434).
- mice treated with selective adenosine A 3 receptor antagonists showed marked attenuation of pulmonary inflammation, reducing eosinophil infiltration and production of airway mucus (Young, HW; et al, A 3 adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice. J. Immunol. 2004, 173, 1380-1389).
- adenosine A 3 receptors Modulation of adenosine A 3 receptors has been reported as a possible therapeutic target for the treatment of various eye diseases, such as dry eye syndrome, glaucoma or uveitis (Y. Zhong, et al, Adenosine, adenosine receptors and glaucoma : An updated overview, Biochim. Biophys. Acta, 2013).
- mRNA and adenosine A 3 receptor protein have been found to be increased in the colorless ciliary epithelium of the eye in glaucoma lens pseudoexfoliation syndrome, compared to the normal eye (Schlotzer-Schrehardt, U. ; et al, Selective upregulation I heard the A 3 adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma. Invest. Ophthalmol. Visual Sci. 2005, 46, 2023-2034).
- IB-MECA anti-inflammatory and protective effects mediated by A 3 ARs have led us to analyze the effect of IB-MECA in an experimental autoimmune uveitis model that represents human uveitis with an autoimmune etiology.
- IB-MECA inhibits the clinical and pathological manifestations of uveitis (Bar-Yehuda, S .; et al, Inhibition of experimental auto-immune uveitis by the A3 adenosine agonist receptor CF101. Int. J. Mol. Med. 201 1, 28, 727-731).
- a 3 ARs are present in different types of tumor cells, such as the HL60 and K562 human tumor lines of leukemia and lymphoma, glioblastoma and prostate.
- a 3 ARs are involved in tumor growth and cell cycle regulation (Gessi, S .; et al, Adenosine receptors in colon carcinoma tissues and colon tumor cell Unes: focus on the A 3 adenosine subtype. J. Cell. Physiol. 2007, 21 1, 826-836).
- patent application US 200320387 discloses derivatives of 2,4-substituted tlazoles, having inhibitory properties on the production of pro-inflammatory cytokines and inhibition on said adenosine A 3 receptor.
- Patent application WO 9921555 discloses compounds derived from 1,3-azoles as antagonists of adenosine A 3 receptor and their use as a prophylactic or therapeutic agent for the treatment of asthma, allergies and inflammation, among others.
- aryl-pyridinyl-thiazoles are disclosed as adenosine A 3 receptor inhibitors and their use also as anti-inflammatory agents.
- US patent application 2012134945 discloses the use of adenosine A 3 receptor antagonists in the modulation of melanin production, secretion and / or accumulation, as well as methods of treating conditions such as skin hyperpigmentation.
- Patent application US 201 1190324 discloses the use of adenosine A 3 receptor antagonists for the treatment of atherosclerosis and the combination of said antagonists with other anti-atherosclerotic agents.
- US patent application 171130 discloses the use of antagonists and / or partial agonists of adenosine A 3 receptor for the treatment of numerous diseases, including cancer, inflammatory diseases, asthma, glaucoma, among others.
- numerous diseases including cancer, inflammatory diseases, asthma, glaucoma, among others.
- adenosine A 3 receptor antagonists related to the treatment of glaucoma and with the decrease in intraocular pressure in general, several patent documents have been found that disclose different types of adenosine A 3 receptor antagonists, as can be seen in WO 0003741, WO 2008045330 and US 2012053176.
- the present invention relates to derivatives of 1- (5- (thiazol-2-ylcarbamoyl) pyridin-2-yl) piperidine-4-carboxylic acid of formula (I):
- R 1 represents a 5- or 6-membered heteroaryl group or a phenyl group optionally substituted by 1, 2 or 3 substituents selected from the group consisting of halogen atom, linear or branched haloalkyl CC 6, linear or branched CC 6 alkyl, CC alkoxy 6 linear or branched and cyano group;
- a) pharmaceutically acceptable salts of said compounds b) pharmaceutical compositions comprising an effective amount of said compounds or their pharmaceutically acceptable salts, c) the use of said compounds in the manufacture of a medicament for treat a disease that can be improved by modulation of adenosine A 3 receptors, selected from the group consisting of atherosclerosis, asthma, prostate cancer, acute renal failure, rheumatoid arthritis, psoriasis, immune thrombocytopenia, Crohn's disease, colitis, syndrome irritable bowel, glaucoma, dry eye syndrome, uveitis and neuropathic pain d) procedures to treat a disease that can be improved by modulation of adenosine A 3 receptors such as cardiovascular diseases such as atherosclerosis, asthma, prostate cancer, acute renal failure , rheumatoid arthritis, psoriasis, immune thrombocytopenia, sick Crohn's d, colitis, irritable bowel
- the therapeutic agent is selected from the group consisting of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase) inhibitors also known as statins, among which are atorvastatin, rosuvastatin and simvastatin, receptor antagonists of leukotriene such as Montelukast, gonadotropin-releasing hormone (GnRH) agonist such as Bicalutamide, anti-androgen medications such as Flutamide, Janusquinase 1 and 3 enzyme inhibitors (JAK 1 and 3) such as Tofacitinib, diuretic agents such as Hydrochlorothiazide and activators of intestinal fluid secretion such as Lubiprostone.
- the additional therapeutic agent is selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, Montelukast, Bicalutamide, Flutamide, Tofacitinib, Hydrochlorothiazide and Lubiprostone.
- CC 6 alkyl group is used to designate linear or branched, optionally substituted hydrocarbon (C n H 2 n + i) radicals having 1 to 6 carbon atoms.
- the alkyl groups preferably contain from 1 to 4 carbon atoms.
- alkyl groups are: methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl and tere-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, isopentyl, 1- ethylpropyl, 1 , 1-dimethylpropyl, 1,2-dimethylpropyl, n-hexyl, 1-ethylbutyl, 2-ethylbutyl, 1, 1- dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3 -dimethylbutyl, 2- methylpentyl, 3-methylpentyl and iso-hexyl.
- CC 6 alkoxy group is used to designate radicals containing the CC 6 alkyl group attached to an oxygen atom (C 2 H 2 n + i-0-), linear or branched, optionally substituted, containing 1 to 6 carbon atoms.
- the alkyl groups contain 1 to 4 carbon atoms.
- Examples of preferred alkoxy groups are: methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, sec-butoxy, t-butoxy, trifluoromethoxy, difluoromethoxy, hydroxy methoxy, 2-hydroxyethoxy or 2-hydroxypropoxy.
- heteroaryl group is used to designate a ring of 5 or 6 members, which have one, two or three heteroatom, selected from O, S and N.
- the heteroaryl groups in the present invention may be optionally substituted.
- the preferred heteroaryl groups are thienyl, furyl, pyridyl and thiazolyl.
- the substituents may be the same or different.
- heteroaryl groups include pyrazinyl, pyrimidinyl, pyridazinyl, furyl, oxadiazolyl, oxazolyl, imidazolyl, -1,3-thiazolyl, thiadiazolyl, and pyrazolyl.
- CC 6 haloalkyl consists of an alkyl group as defined above, attached to 1, 2 or 3 halogen atoms, such as chlorine, fluorine, bromine or iodine. Preferred halogen atoms are chlorine and fluorine.
- atoms, groups, radicals, moieties, chains or cycles present in the general structures of the invention are "optionally substituted.” This means that these atoms, groups, radicals, moieties, chains or cycles may be unsubstituted or substituted in any position by one or more substituents, for example 1, 2, 3 or 4 substituents, in which the hydrogen atoms attached to atoms, groups, radicals, moieties, chains or unsubstituted cycles are substituted by halogen atoms, cycloalkyl C 3 -C 12, hydroxy, alkoxy CC 6 linear or branched, CC 6 alkylthio, amino, mono- or dialkylamino, alkoxyalkyl CC 6 , hydroxycarbonyl and C 2 -C 6 alkoxycarbonyl.
- substituents for example 1, 2, 3 or 4 substituents, in which the hydrogen atoms attached to atoms, groups, radicals, moieties, chains or unsubstituted cycles are substituted by
- the term "pharmaceutically acceptable salt” encompasses salts with a pharmaceutically acceptable acid or base.
- Pharmaceutically acceptable acids include inorganic acids, for example, hydrochloric, sulfuric, phosphoric, diphosphoric, hydrobromic, hydroiodic and nitric acids and organic acids, for example, citric, maleic, malic, mandelic, ascorbic, oxalic, succinic, tartaric, acetic acids. , methanesulfonic, ethanesulfonic, benzenesulfonic or p-toluenesulfonic.
- Pharmaceutically acceptable bases include alkali metal hydroxides (for example, sodium or potassium and alkaline earth metals (for example, calcium or magnesium) and organic bases, for example, alkylamines, arylalkylamines and heterocyclic amines.
- alkali metal hydroxides for example, sodium or potassium and alkaline earth metals (for example, calcium or magnesium)
- organic bases for example, alkylamines, arylalkylamines and heterocyclic amines.
- Other preferred salts according to the invention are quaternary ammonium compounds in which an equivalent of an anion (X-) is associated with the positive charge of the atom of N.
- X " can be an anion of various mineral acids such as, for example, chloride , bromide, iodide, sulfate, nitrate, phosphate or an anion of an organic acid, such as acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, trifluoroacetate, methanesulfonate and p-toluenesulfonate.
- mineral acids such as, for example, chloride , bromide, iodide, sulfate, nitrate, phosphate or an anion of an organic acid, such as acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, trifluoroacetate, methanesulfonate and p-toluenesulfonate.
- an anion selected from chloride, bromide, iodide, sulfate, nitrate, acetate, maleate, oxalate, succinate or trifluoroacetate More preferably X- is chloride, bromide, trifluoroacetate or methanesulfonate.
- R 1 represents a 5- or 6-membered heteroaryl group optionally substituted by 1, 2 or 3 substituents selected from the group consisting of halogen atom, linear CC 6 haloalkyl or branched, linear or branched CC 6 alkyl, linear or branched CC 6 alkoxy and cyano group.
- R 1 represents a group that is selected from thienyl, furyl, pyridyl and thiazolyl optionally substituted by 1, 2 or 3 substituents selected from the group consisting of halogen atom, linear CC 6 alkyl or branched, linear or branched CC 6 alkoxy and cyano group.
- R 1 represents a thienyl group optionally substituted by 1, 2 or 3 substituents selected from the group consisting of halogen atom and linear or branched CC 6 alkoxy.
- R 1 represents a phenyl group optionally substituted by 1, 2 or 3 substituents selected from the group consisting of halogen atom, haloalkyl CC 6 linear or branched, CC 6 alkyl linear or branched, linear or branched CC 6 alkoxy and cyano group.
- R 1 represents a phenyl group optionally substituted by 1, 2 or 3 substituents selected from the group consisting of halogen atom and linear or branched CC 6 alkoxy.
- Particular individual compounds of the invention include: 1- (5- (5-Cyano-4-phenylthiazol-2-ylcarbamoyl) pyridin-2-yl) piperidine-4-carboxylic acid 1- (5 - ((5-Cyano-4- (2-methoxyphenyl) thiazol-2-yl) carbamoyl) pyridin-2-yl) piperidine-4-carboxylic acid
- the 2-amino-4-cyano-1,3-thiazoles of formula (III) can be obtained by the reaction between the commercial cyanoketones used of formula (II) with iodine and thiourea at temperatures between 40 ° to 100 ° C and pyridine as solvent as shown in scheme 1.
- Non-commercial cyanoketones (II) can be synthesized from the reaction of the corresponding esters (IV) with acetonitrile in DMSO in the presence of sodium hydride, following methods known in the state of the art. The derivatives of formula (II) obtained are subsequently used without further purification.
- the 2-amino-4-cyano-1,3-thiazoles (III) react with the commercial esters of formula (V), to give rise to the amides of formula (VI), which in turn are transformed into derivatives of formula (VIII) when they react with the corresponding commercial amines of formula (VII) such as methyl isonipecotate in DMSO at temperatures between 60 ° and 100 ° C over a period of 4 to 12 hours.
- the binding assay of adenosine receptor subtype 2 b is carried out using a recombinant human source (HEK-293 cells) and [3 H] DPCPX as radioligand, according to the assay described by Fredholm et al. (International Union of Pharmacology XXV nomenclature and classification of adenosine receptors, Pharmacol Rev. 2001 December; 53 (4): 527-52).
- Another aspect of the present invention is directed to the use of a compound of formula (I) according to the present invention for the manufacture of a medicament for the treatment of a disease or pathological condition that can be improved by the modulation of adenosine A 3 receptors. .
- the compounds of the present invention are useful in the treatment or prevention of diseases that are known to be improved by modulation of adenosine A 3 receptors, such as cardiovascular diseases such as atherosclerosis, respiratory diseases such as asthma, cancer diseases such as cancer. prostate, kidney diseases such as acute renal failure, autoimmune diseases such as rheumatoid arthritis, diseases of the gastrointestinal system such as Crohn's disease, colitis or irritable bowel syndrome or ophthalmic diseases or conditions such as glaucoma, dry eye syndrome or uveitis.
- cardiovascular diseases such as atherosclerosis
- respiratory diseases such as asthma
- cancer diseases such as cancer.
- prostate kidney diseases such as acute renal failure
- autoimmune diseases such as rheumatoid arthritis
- diseases of the gastrointestinal system such as Crohn's disease, colitis or irritable bowel syndrome or ophthalmic diseases or conditions
- glaucoma dry eye syndrome or uveitis.
- the compounds of the invention, the pharmaceutically acceptable salts thereof, and the pharmaceutical compositions comprising said compounds and / or the salts thereof can be used in a method of treating disorders of the human body comprising administering to a subject in need of said treatment an effective amount of a 2-amino-1, 3-thiazole derivative of formula (I) of the invention or a pharmaceutically acceptable salt thereof.
- the present invention also provides pharmaceutical compositions comprising, as active ingredient, at least one 2-amino-1,3-thiazole derivative of formula (I) according to the present invention or a pharmaceutically acceptable salt thereof, together with a pharmaceutically excipient. acceptable, such as a vehicle or diluent.
- a pharmaceutically excipient such as a vehicle or diluent.
- the active ingredient may comprise from 0.001% to 99% by weight, preferably from 0.01% to 90% by weight of the composition, depending on the nature of the formulation and whether an additional dilution is made before application.
- the compositions are prepared in a form suitable for oral, topical, nasal, rectal, percutaneous or injectable administration.
- compositions of this invention are well known per se and the actual excipients used depend on the intended method of administration of the compositions.
- compositions of this invention are preferably adapted for injectable administration and per os.
- the compositions for oral administration may take the form of tablets, long-acting tablets, sublingual tablets, capsules, inhalation aerosols, inhalation solutions, dry inhalation powder or liquid preparations, such as mixtures, elixirs, syrups or suspensions, all of them containing the compound of the invention;
- Such preparations can be prepared by methods known in the art.
- Diluents that can be used in the preparation of the compositions include liquid and solid diluents that are compatible with the active ingredient, together with coloring or flavoring agents, if desired.
- the tablets or capsules may conveniently contain between 2 and 500 mg of the active ingredient or the equivalent amount of a salt thereof.
- the liquid composition adapted for oral use may be in the form of solutions or suspensions.
- the solutions may be aqueous solutions of a soluble salt or other derivative of the active compound together with, for example, sucrose to form a syrup.
- the suspensions may comprise an insoluble active compound of the invention or a pharmaceutically acceptable salt thereof together with water, together with a suspending agent or a flavoring agent.
- compositions for parenteral injection may be prepared from soluble salts, which may or may not be dried by freezing and may be dissolved in a pyrogen-free aqueous medium or other fluid suitable for parenteral injection.
- Effective doses are usually in the range of 2-2000 mg of active ingredient per day.
- the daily dosage can be administered in one or more treatments, preferably 1 to 4 treatments, per day.
- Another aspect of the invention is directed to a combination product comprising a compound of formula (I) as defined above and other drugs approved to treat diseases of the central nervous system such as Alzheimer's disease, cardiovascular diseases such as for example, atherosclerosis, respiratory diseases such as asthma, kidney diseases such as acute renal failure, cancer diseases such as prostate cancer, autoimmune diseases such as rheumatoid arthritis or diseases of the gastrointestinal system such as colon syndrome irritable.
- cardiovascular diseases such as for example, atherosclerosis
- respiratory diseases such as asthma
- kidney diseases such as acute renal failure
- cancer diseases such as prostate cancer
- autoimmune diseases such as rheumatoid arthritis or diseases of the gastrointestinal system such as colon syndrome irritable.
- HMG-CoA reductase also known as statins, including atorvastatin, rosuvastatin and simvastatin, leukotriene receptor antagonists such as Montelukast, gonadotropin-releasing hormone (GnRH) agonist such as Bicalutamide, antiandrogen medications such as Flutamide, Janusquinase 1 and 3 enzyme inhibitors (JAK 1 and 3) such as Tofacitinib, diuretic agents such as Hydrochlorothiazide and activators of intestinal fluid secretion such as Lubiprostone.
- statins including atorvastatin, rosuvastatin and simvastatin, leukotriene receptor antagonists such as Montelukast, gonadotropin-releasing hormone (GnRH) agonist such as Bicalutamide, antiandrogen medications such as Flutamide, Janusquinase 1 and 3 enzyme inhibitors (JAK 1 and 3) such as Tofacitinib,
- reaction products were purchased from commercial sources.
- concentration refers to evaporation under vacuum using a Büchi rotary evaporator.
- reaction products were purified by flash chromatography on silica gel (40-63 ⁇ ) with the indicated solvent system.
- Thermoquest Fennigan aQa Thermoquest Fennigan aQa.
- Example 1 1 - (5- (5-Cyano-4-phenylthiazol-2-ylcarbamoyl) pyridin-2-yl) piperidine-4-carboxylic acid
- Example 3 1 - (5 - ((5-Cyano-4- (3-methoxyphenyl) thiazol-2-yl) carbamoyl) pyridin-2-yl) piperidin-4-carboxylic acid
- 1 H-NMR (400 MHz, DMSO -d 6 ): ⁇ 13.32 (s, 1H), 8.88 (d, 1H), 8.23 (m, 1H), 7.62 (dd, 1H), 7.57 (d, 1H ), 7.50 (t, 1H), 7.12 (dd, 1H), 7.02 (d, 1H), 4.36 (d, 2H), 3.83 (s, 3H), 3.16 (t, 2H), 2.60 (t, 1H), 1.91 (d, 2H), 1.54 (dd, 2H).
- Example 5 1 - (5 - ((5-cyano-4- (2-fluorophenyl) thiazol-2-yl) carbamoyl) pyridin-2- yl) piperidin-4-carboxylic acid
- Example 7 1 - (5 - ((5-cyano-4- (4-fluorophenyl) thiazol-2-yl) carbamoyl) pyridin-2- yl) piperidine-4-carboxylic acid
- Example 8 1 - (5 - ((4- (2-chlorophenyl) -5-cyanothiazol-2-yl) carbamoyl) pyridin-2- yl) piperidin-4-carboxylic acid
- 1 H-NMR (400 MHz, DMSO- d 6 ): ⁇ 13.33 (s, 1H), 12.30 (s, 1H), 8.88 (d, 1H), 8.20 (dd, 1H), 7.66 (m, 2H) , 7.55 (d, 2H), 6.96 (d, 1H), 4.36 (d, 2H), 3.12 (t, 2H), 2.59 (d, 1H), 1.90 ( d, 2H), 1.51 (m, 2H).
- Example 10 1 - (5 - ((5-cyano-4- (pyridin-3-yl) thiazol-2-yl) carbamoyl) pyridin-2- yl) piperidine-4-carboxylic acid
- Example 12 1 - (5- (5-Cyano-4- (6-methoxypyridin-3-yl) thiazol-2-ylcarbamoyl) pyridin-2-yl) piperidine-4-carboxylic acid
- Example 13 1 - (5- (5-Cyano-4- (furan-2-yl) thiazol-2-ylcarbamoyl) pyridin-2- yl) piperidine-4-carboxylic acid
- Example 15 1- (5- (5-Cyano-4- (thiophene-3-yl) thiazol-2-ylcarbamoyl) pyridin-2-yl) piperidine-4-carboxylic acid.
- Example 16 1 - (5 - ((4- (4-chlorothiophene-2-yl) -5-cyanothiazol-2-yl) carbamoyl) pyridin-2-yl) piperidine-4-carboxylic acid
- Example 17 1 - (5- (5-Cyano-4- (thiazol-2-yl) thiazol-2-ylcarbamoyl) pyridin-2- yl) piperidine-4-carboxylic acid
- 1 H-NMR (400 MHz, DMSO- d 6 ): ⁇ 13.36 (s, 1H), 12.28 (s, 1H), 8.89 (d, 1H), 8.20 (dd, 1H), 8.12 (d, 1H) , 8.02 (d, 1H), 6.95 (d, 1H), 4.36 (d, 2H), 3.12 (t, 2H), 2.59 (m, 1H), 1.90 ( d, 2H), 1.52 (dd, 2H).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112019012464A BR112019012464A2 (pt) | 2017-01-20 | 2018-01-19 | moduladores dos receptores a3 de adenosina |
ES18716648T ES2847385T3 (es) | 2017-01-20 | 2018-01-19 | Moduladores de los receptores A3 de adenosina |
KR1020197021292A KR102483091B1 (ko) | 2017-01-20 | 2018-01-19 | 아데노신 a3 수용체의 조절제 |
US16/479,448 US10744125B2 (en) | 2017-01-20 | 2018-01-19 | Adenosine A3 receptor modulators |
LTEP18716648.3T LT3581572T (lt) | 2017-01-20 | 2018-01-19 | Adenozino a3 receptoriaus moduliatoriai |
CA3048604A CA3048604A1 (en) | 2017-01-20 | 2018-01-19 | Modulators of the adenosine a3 receptors |
RS20210117A RS61424B1 (sr) | 2017-01-20 | 2018-01-19 | Modulatori adenozinskog a3 receptora |
MX2019008554A MX2019008554A (es) | 2017-01-20 | 2018-01-19 | Moduladores de los receptores a3 de adenosina. |
SI201830194T SI3581572T1 (sl) | 2017-01-20 | 2018-01-19 | Modulatorji adenozin A3 receptorja |
EA201991728A EA038011B1 (ru) | 2017-01-20 | 2018-01-19 | Модуляторы аденозиновых рецепторов a3 |
AU2018209271A AU2018209271B2 (en) | 2017-01-20 | 2018-01-19 | Adenosine A3 receptor modulators |
DK18716648.3T DK3581572T3 (da) | 2017-01-20 | 2018-01-19 | Adenosin-A3-receptormodulatorer |
EP18716648.3A EP3581572B8 (en) | 2017-01-20 | 2018-01-19 | Adenosine a3 receptor modulators |
PL18716648T PL3581572T3 (pl) | 2017-01-20 | 2018-01-19 | Modulatory receptora adenozynowego A3 |
CN201880007819.7A CN110198939B (zh) | 2017-01-20 | 2018-01-19 | 腺苷a3受体的调节剂 |
JP2019538476A JP7032410B2 (ja) | 2017-01-20 | 2018-01-19 | アデノシンa3受容体の調節剤 |
ZA2019/04333A ZA201904333B (en) | 2017-01-20 | 2019-07-01 | Adenosine a3 receptor modulators |
HRP20210052TT HRP20210052T1 (hr) | 2017-01-20 | 2021-01-12 | Modulatori adenozinskog receptora a3 |
CY20211100094T CY1123843T1 (el) | 2017-01-20 | 2021-02-04 | Ρυθμιστες υποδοχεων α3 αδενοσινης |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP201730065 | 2017-01-20 | ||
ES201730065A ES2676535B1 (es) | 2017-01-20 | 2017-01-20 | Moduladores de los receptores a3 de adenosina |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018134464A1 true WO2018134464A1 (es) | 2018-07-26 |
Family
ID=61913194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2018/070039 WO2018134464A1 (es) | 2017-01-20 | 2018-01-19 | Moduladores de los receptores a3 de adenosina |
Country Status (22)
Country | Link |
---|---|
US (1) | US10744125B2 (es) |
EP (1) | EP3581572B8 (es) |
JP (1) | JP7032410B2 (es) |
KR (1) | KR102483091B1 (es) |
CN (1) | CN110198939B (es) |
AU (1) | AU2018209271B2 (es) |
BR (1) | BR112019012464A2 (es) |
CA (1) | CA3048604A1 (es) |
CY (1) | CY1123843T1 (es) |
DK (1) | DK3581572T3 (es) |
EA (1) | EA038011B1 (es) |
ES (2) | ES2676535B1 (es) |
HR (1) | HRP20210052T1 (es) |
HU (1) | HUE052437T2 (es) |
LT (1) | LT3581572T (es) |
MX (1) | MX2019008554A (es) |
PL (1) | PL3581572T3 (es) |
PT (1) | PT3581572T (es) |
RS (1) | RS61424B1 (es) |
SI (1) | SI3581572T1 (es) |
WO (1) | WO2018134464A1 (es) |
ZA (1) | ZA201904333B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020152645A (ja) * | 2019-03-18 | 2020-09-24 | 公立大学法人横浜市立大学 | 抗動脈硬化剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3957308A1 (en) * | 2020-08-21 | 2022-02-23 | Palobiofarma, S.L. | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999021555A2 (en) | 1997-10-27 | 1999-05-06 | Takeda Chemical Industries, Ltd. | Adenosine a3 receptor antagonists |
WO1999064418A1 (en) | 1998-06-05 | 1999-12-16 | Novartis Ag | Aryl pyridinyl thiazoles |
WO2000003741A2 (en) | 1998-07-16 | 2000-01-27 | The Trustees Of The University Of Pennsylvania | Methods for reducing intraocular pressure using a3-adenosine antagonists |
EP1180518A1 (en) | 1999-04-23 | 2002-02-20 | Takeda Chemical Industries, Ltd. | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof |
US20030020387A1 (en) | 2001-07-16 | 2003-01-30 | Wing Forrest F. | Refrigerator shelves with rolled hook for cantilever fastening |
ES2204262A1 (es) | 1998-09-16 | 2004-04-16 | Medco Research Inc. | Moduladores de los receptores a 3 de adenosina. |
WO2005009969A1 (en) | 2003-07-31 | 2005-02-03 | Sanofi-Aventis | Aminoquinoline derivatives and their use as adenosine a3 ligands |
WO2007116106A1 (es) * | 2006-04-12 | 2007-10-18 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina |
WO2008006369A1 (en) | 2006-07-14 | 2008-01-17 | Santaris Pharma A/S | Adenosine receptor antagonists |
WO2008045330A2 (en) | 2006-10-06 | 2008-04-17 | The Trustees Of The University Of Pennsylvania | Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure |
WO2009044250A1 (en) * | 2007-10-02 | 2009-04-09 | Palobiofarma, S.L. | New compounds as adenosine a1 receptor antagonists |
WO2009052310A1 (en) | 2007-10-16 | 2009-04-23 | Cv Therapeutics, Inc | A3 adenosine receptor antagonists |
ES2360632T3 (es) | 2006-01-26 | 2011-06-07 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Moduladores alostéricos del receptor a3 de adenosina. |
US20110171130A1 (en) | 2008-08-01 | 2011-07-14 | The United States of America, as represented by the Secretary ,Deptment of Health and HumanService | A3 adenosine receptor antagonists and partial agonists |
US20110190324A1 (en) | 2008-07-16 | 2011-08-04 | Edward Leung | Methods of treating atherosclerosis |
US20120053176A1 (en) | 2010-09-01 | 2012-03-01 | Ambit Biosciences Corp. | Adenosine a3 receptor modulating compounds and methods of use thereof |
US20120134945A1 (en) | 2009-07-21 | 2012-05-31 | Oradin Pharmaceutical Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
WO2016116652A1 (es) * | 2015-01-22 | 2016-07-28 | Palobiofarma, S.L. | Moduladores de los receptores a3 de adenosina |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09291089A (ja) * | 1996-04-26 | 1997-11-11 | Yamanouchi Pharmaceut Co Ltd | 新規な5−チアゾリルウラシル誘導体又はその塩 |
JP3333774B2 (ja) | 1999-04-23 | 2002-10-15 | 武田薬品工業株式会社 | 5−ピリジル−1,3−アゾール化合物、その製造法及び用途 |
JP2003525291A (ja) | 2000-03-01 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 2,4−二置換チアゾリル誘導体 |
US6358964B1 (en) * | 2000-07-26 | 2002-03-19 | King Pharmaceuticals Research And Development, Inc. | Adenosine, A3 receptor modulators |
GB0028383D0 (en) * | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
EP3002283B1 (en) | 2003-12-26 | 2017-06-14 | Kyowa Hakko Kirin Co., Ltd. | Thiazole derivatives |
WO2009010871A2 (en) * | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Pyrazole derivatives as antagonists of adenosine a3 receptor |
ES2896354T3 (es) * | 2012-12-21 | 2022-02-24 | Astellas Inst For Regenerative Medicine | Métodos para la producción de plaquetas a partir de células madre pluripotentes |
-
2017
- 2017-01-20 ES ES201730065A patent/ES2676535B1/es active Active
-
2018
- 2018-01-19 CN CN201880007819.7A patent/CN110198939B/zh active Active
- 2018-01-19 PT PT187166483T patent/PT3581572T/pt unknown
- 2018-01-19 JP JP2019538476A patent/JP7032410B2/ja active Active
- 2018-01-19 WO PCT/ES2018/070039 patent/WO2018134464A1/es unknown
- 2018-01-19 KR KR1020197021292A patent/KR102483091B1/ko active IP Right Grant
- 2018-01-19 US US16/479,448 patent/US10744125B2/en active Active
- 2018-01-19 EP EP18716648.3A patent/EP3581572B8/en active Active
- 2018-01-19 CA CA3048604A patent/CA3048604A1/en active Pending
- 2018-01-19 AU AU2018209271A patent/AU2018209271B2/en active Active
- 2018-01-19 DK DK18716648.3T patent/DK3581572T3/da active
- 2018-01-19 LT LTEP18716648.3T patent/LT3581572T/lt unknown
- 2018-01-19 EA EA201991728A patent/EA038011B1/ru unknown
- 2018-01-19 BR BR112019012464A patent/BR112019012464A2/pt active Search and Examination
- 2018-01-19 MX MX2019008554A patent/MX2019008554A/es unknown
- 2018-01-19 PL PL18716648T patent/PL3581572T3/pl unknown
- 2018-01-19 RS RS20210117A patent/RS61424B1/sr unknown
- 2018-01-19 SI SI201830194T patent/SI3581572T1/sl unknown
- 2018-01-19 ES ES18716648T patent/ES2847385T3/es active Active
- 2018-01-19 HU HUE18716648A patent/HUE052437T2/hu unknown
-
2019
- 2019-07-01 ZA ZA2019/04333A patent/ZA201904333B/en unknown
-
2021
- 2021-01-12 HR HRP20210052TT patent/HRP20210052T1/hr unknown
- 2021-02-04 CY CY20211100094T patent/CY1123843T1/el unknown
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999021555A2 (en) | 1997-10-27 | 1999-05-06 | Takeda Chemical Industries, Ltd. | Adenosine a3 receptor antagonists |
WO1999064418A1 (en) | 1998-06-05 | 1999-12-16 | Novartis Ag | Aryl pyridinyl thiazoles |
WO2000003741A2 (en) | 1998-07-16 | 2000-01-27 | The Trustees Of The University Of Pennsylvania | Methods for reducing intraocular pressure using a3-adenosine antagonists |
ES2204262A1 (es) | 1998-09-16 | 2004-04-16 | Medco Research Inc. | Moduladores de los receptores a 3 de adenosina. |
EP1180518A1 (en) | 1999-04-23 | 2002-02-20 | Takeda Chemical Industries, Ltd. | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof |
US20030020387A1 (en) | 2001-07-16 | 2003-01-30 | Wing Forrest F. | Refrigerator shelves with rolled hook for cantilever fastening |
WO2005009969A1 (en) | 2003-07-31 | 2005-02-03 | Sanofi-Aventis | Aminoquinoline derivatives and their use as adenosine a3 ligands |
ES2360632T3 (es) | 2006-01-26 | 2011-06-07 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Moduladores alostéricos del receptor a3 de adenosina. |
WO2007116106A1 (es) * | 2006-04-12 | 2007-10-18 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina |
WO2008006369A1 (en) | 2006-07-14 | 2008-01-17 | Santaris Pharma A/S | Adenosine receptor antagonists |
WO2008045330A2 (en) | 2006-10-06 | 2008-04-17 | The Trustees Of The University Of Pennsylvania | Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure |
WO2009044250A1 (en) * | 2007-10-02 | 2009-04-09 | Palobiofarma, S.L. | New compounds as adenosine a1 receptor antagonists |
WO2009052310A1 (en) | 2007-10-16 | 2009-04-23 | Cv Therapeutics, Inc | A3 adenosine receptor antagonists |
US20110190324A1 (en) | 2008-07-16 | 2011-08-04 | Edward Leung | Methods of treating atherosclerosis |
US20110171130A1 (en) | 2008-08-01 | 2011-07-14 | The United States of America, as represented by the Secretary ,Deptment of Health and HumanService | A3 adenosine receptor antagonists and partial agonists |
US20120134945A1 (en) | 2009-07-21 | 2012-05-31 | Oradin Pharmaceutical Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
US20120053176A1 (en) | 2010-09-01 | 2012-03-01 | Ambit Biosciences Corp. | Adenosine a3 receptor modulating compounds and methods of use thereof |
WO2016116652A1 (es) * | 2015-01-22 | 2016-07-28 | Palobiofarma, S.L. | Moduladores de los receptores a3 de adenosina |
Non-Patent Citations (34)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020152645A (ja) * | 2019-03-18 | 2020-09-24 | 公立大学法人横浜市立大学 | 抗動脈硬化剤 |
JP7233087B2 (ja) | 2019-03-18 | 2023-03-06 | 公立大学法人横浜市立大学 | 抗動脈硬化剤 |
Also Published As
Publication number | Publication date |
---|---|
ES2676535A1 (es) | 2018-07-20 |
EA201991728A1 (ru) | 2019-12-30 |
RS61424B1 (sr) | 2021-03-31 |
DK3581572T3 (da) | 2021-01-18 |
KR20190105226A (ko) | 2019-09-16 |
PL3581572T3 (pl) | 2021-05-31 |
CN110198939A (zh) | 2019-09-03 |
LT3581572T (lt) | 2021-02-25 |
ES2676535B1 (es) | 2019-04-29 |
ZA201904333B (en) | 2020-12-23 |
EP3581572B1 (en) | 2020-11-25 |
JP7032410B2 (ja) | 2022-03-08 |
HRP20210052T1 (hr) | 2021-03-05 |
US20190374530A1 (en) | 2019-12-12 |
PT3581572T (pt) | 2021-02-09 |
MX2019008554A (es) | 2019-09-19 |
EP3581572A1 (en) | 2019-12-18 |
KR102483091B1 (ko) | 2023-01-02 |
CY1123843T1 (el) | 2022-05-27 |
AU2018209271B2 (en) | 2021-03-11 |
BR112019012464A2 (pt) | 2020-04-14 |
HUE052437T2 (hu) | 2021-04-28 |
JP2020505349A (ja) | 2020-02-20 |
CN110198939B (zh) | 2023-03-28 |
EA038011B1 (ru) | 2021-06-22 |
EP3581572B8 (en) | 2021-03-24 |
US10744125B2 (en) | 2020-08-18 |
CA3048604A1 (en) | 2018-07-26 |
SI3581572T1 (sl) | 2021-04-30 |
AU2018209271A1 (en) | 2019-07-04 |
ES2847385T3 (es) | 2021-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2293045T3 (es) | Derivados de benzofurano, procedimiento para su preparacion, e intermedios de los mismos. | |
JP6181744B2 (ja) | 血小板凝集を治療するためのプロテアーゼ活性化受容体4(par4)阻害剤としてのイミダゾチアジアゾール誘導体 | |
ES2935173T3 (es) | Composiciones farmacéuticas que comprenden derivados de imidazotiadiazol e imidazopiridazina como inhibidores del receptor activado por proteasa 4 (PAR4) para tratar la agregación plaquetaria | |
TWI438205B (zh) | 蛋白質酪胺酸激酶活性抑制劑 | |
ES2864800T3 (es) | Compuesto de benzamida sustituida con alquinilo 5-aromático y procedimiento de preparación, composición farmacéutica, y uso del mismo | |
ES2910071T3 (es) | Compuestos de aminopirazina diol como inhibidores de PI3K-Y | |
ES2824801T3 (es) | Sal de compuesto heterocíclico sustituido con halógeno | |
CA3071900A1 (en) | Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | |
ES2847385T3 (es) | Moduladores de los receptores A3 de adenosina | |
ES2750030T3 (es) | Moduladores De Los Receptores A3 De Adenosina | |
WO2021104486A1 (zh) | 一种含苯环的化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18716648 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019012464 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 3048604 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2018209271 Country of ref document: AU Date of ref document: 20180119 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019538476 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20197021292 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018716648 Country of ref document: EP Effective date: 20190820 |
|
ENP | Entry into the national phase |
Ref document number: 2018716648 Country of ref document: EP Effective date: 20190820 |
|
ENP | Entry into the national phase |
Ref document number: 112019012464 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190617 |